Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Total Liabilities of $1.3 billion for Q1 2026, down 19.22% year-over-year from $1.7 billion in Q1 2025, and up 3.15% quarter-over-quarter from $1.3 billion in Q4 2025.
Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Total Liabilities history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Total Liabilities fell 19.22% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 19.22% YoY), while the FY2025 annual figure was $1.3 billion, down 21.31% from the prior year.
- Total Liabilities for Q1 2026 stood at $1.3 billion, up from $1.3 billion in the prior quarter.
- The five-year high for Total Liabilities was $1.9 billion in Q4 2023, with the low at $1.3 billion in Q4 2025.
- The 5-year median for Total Liabilities is $1.7 billion (2024), against an average of $1.6 billion.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities grew 13.04% in 2023, then dropped 21.31% in 2025.
- Indivior Pharmaceuticals' Total Liabilities stood at $1.7 billion in 2022, then advanced by 13.04% to $1.9 billion in 2023, then dropped by 14.93% to $1.7 billion in 2024, then decreased by 21.31% to $1.3 billion in 2025, then advanced by 3.15% to $1.3 billion in 2026.
- Business Quant data shows INDV's Total Liabilities at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.12 Bn |
| 10 | Indivior Pharmaceuticals | 4.54 Bn | 4.31 Bn | 294.00 Mn | 1.44 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Bn |
| Mar 31, 2026 | 1.34 Bn |
| Dec 31, 2025 | 1.30 Bn |
| Sep 30, 2025 | 1.62 Bn |
| Jun 30, 2025 | 1.71 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.65 Bn |
| Dec 31, 2023 | 1.94 Bn |
| Dec 31, 2022 | 1.72 Bn |
| Dec 31, 2021 | 1.63 Bn |